Search Within

Dermatology

  1. "Endocrinology"
Formats
  1. Meeting Abstract (3)
  2. Review (2)
  3. Book Section (1)
  4. Journal Article (1)
Groups
  1. Department of Medicine (7)
  2. Dermatology Service (7)
  3. Division of Subspecialty Medicine (7)
  4. Endocrinology (7)
  5. Survivorship Research (7)
  6. Solid Tumor Oncology Division (4)

More Groups

People
  1. Mario Lacouture (7)
  2. Azeez Farooki (3)
  3. Azael Freites Martinez (2)
  4. Eliza Geer (2)
  5. Raquel Rozner (2)
  6. Shari Goldfarb (2)

More People

Years
  1. 2024 (1)
  2. 2022 (2)
  3. 2020 (1)
  4. 2019 (2)
  5. 2014 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Breast Cancer Research and Treatment (1)
  3. Journal of the American Academy of Dermatology (1)
  4. Pocket Oncology (1)
  5. Supportive Care in Cancer (1)
  6. npj Breast Cancer (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Mosby Elsevier (1)
  3. Nature Publishing Group (1)
  4. Springer (1)
  5. Springer Verlag (1)
  6. Wolters Kluwer Health | Lippincott Williams & Wilkins (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
    Journal Article

    Gallagher, E. J.; Moore, H.; Lacouture, M. E.; Dent, S. F.; Farooki, A.; Goncalves, M. D.; Isaacs, C.; Johnston, A.; Juric, D.; Quandt, Z.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Shen, S.; Salehi, E.; Farooki, A.; Flory, J.; Williams, D.; Carpio, A.; Chang, C.; Lacouture, M. E.; Andreopoulou, E.; Sardesai, S. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA -mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP)
    Meeting Abstract

    Gallagher, E. J.; Moore, H.; Lacouture, M. E.; Dent, S. F.; Farooki, A.; Goncalves, M. D.; Isaacs, C.; Johnston, A.; Juric, D.; Quandt, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
    Review

    Choi, J.; Anderson, R.; Blidner, A.; Cooksley, T.; Dougan, M.; Glezerman, I.; Ginex, P.; Girotra, M.; Gupta, D.; Johnson, D.; more...
    Supportive Care in Cancer (2020)

    Fulltext@MSK | Save
  • Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
    Meeting Abstract

    Rozner, R. N.; Freites-Martinez, A.; Shapiro, J.; Geer, E. B.; Goldfarb, S.; Lacouture, M. E.
    Journal of the American Academy of Dermatology (2019)

    Fulltext@MSK | Save
  • Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
    Review

    Rozner, R. N.; Freites-Martinez, A.; Shapiro, J.; Geer, E. B.; Goldfarb, S.; Lacouture, M. E.
    Breast Cancer Research and Treatment (2019)

    Fulltext@MSK | Save
  • Neurologic oncology
    Book Section

    Momtaz, P.; Kaley, T. J.; Won, E.; Batlevi, C. L.; Ryder, M.; Lacouture, M. E.
    In Drilon, A. E.; Postow, M. A.; Krug, L. M. (Eds.) Pocket Oncology (2014)

    Fulltext@MSK | Save